Rhenman & Partners Asset Management Ab Gilead Sciences, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $1.2 Billion
- Q3 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 366,500 shares of GILD stock, worth $33.7 Million. This represents 2.56% of its overall portfolio holdings.
Number of Shares
366,500
Previous 238,500
53.67%
Holding current value
$33.7 Million
Previous $16.4 Million
87.74%
% of portfolio
2.56%
Previous 1.62%
Shares
24 transactions
Others Institutions Holding GILD
# of Institutions
1,926Shares Held
992MCall Options Held
10.5MPut Options Held
9.75M-
Black Rock Inc. New York, NY121MShares$11.1 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$10.6 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$7.04 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$5.69 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.54 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $115B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...